K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: A molecular panel correlates with and supplements cytologic diagnosis

American Journal of Clinical Pathology

Volumn 117, Issue 5, 2002, Pages 755-765

  Van Heek, Tjarda ^a   Rader, Anne E ^a   Offerhaus, G Johan A ^a   McCarthy, Denis M ^a   Goggins, Michael ^a   Hruban, Ralph H ^a   Wilentz, Robb E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cytology; Cytopathology; Dpc4; Fine needle aspiration; Genetics; K ras; P53; Pancreas

Indexed keywords

PROTEIN P53; RAS PROTEIN; SMAD4 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ASPIRATION BIOPSY; CONTROLLED STUDY; CYTODIAGNOSIS; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; FOLLOW UP; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS DISEASE; PANCREAS TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; BIOPSY, NEEDLE; DISSECTION; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROMANIPULATION; ONCOGENE PROTEIN P21(RAS); PANCREAS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; SMAD4 PROTEIN; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036239123     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/5RQ0-JCQU-5XF2-51LQ     Document Type: Article

References (50)

1. Genetics of pancreatic cancer: From genes to families
2. Tumor-suppressive pathways in pancreatic carcinoma
3. K-ras oncogene activation in adenocarcinoma of the human pancreas: A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization
4. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions
5. Over-expression of p53 protein in adenocarcinoma of the pancreas
6. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis
7. Pancreatic adenocarcinomas frequently show p53 gene mutations
8. p53, ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas
9. Sensitive detection of loss of heterozygosity in the TP53 gene in pancreatic adenocarcinoma by fluorescence-based single strand conformation polymorphism analysis using blunt end DNA fragments
10. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer
11. DPC4 gene in various tumor types
12. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
13. Homozygous deletion map at 18q21.1 in pancreatic cancer
14. K-ras codon 12 mutations occur very frequently in pancreatic adeno-carcinomas
15. Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients
16. Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing
17. Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma
18. K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions
19. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: Mutation of K-ras and overexpression of the p53 protein product
20. Survival in 1001 patients with carcinoma of the pancreas
21. Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid
22. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas
23. Dpc4 protein in mucinous cystic neoplasms of the pancreas: Frequent loss of expression in invasive carcinomas suggests a role in genetic progression
24. Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation
25. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression
26. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms
27. Immunohistochemical analysis of p53 protein expression in human pancreatic ductal adenocarcinomas and precursor lesions
28. Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors
29. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies
30. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas
31. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens
32. p53 in tumour pathology: Can we trust immunohistochemistry? revisited!
33. Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis
34. Analysis of K-ras oncogene mutation directly applied to atypical cell clusters on cytologic smear slides of bile and pancreatic juice
35. Detection of p53 protein in cytological specimens of pancreatic diseases obtained by selective endoscopic brushing
36. The utility of Ki-ras mutation analysis in the cytologic diagnosis of pancreatobiliary neoplasms
37. The potential diagnostic use of k-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region
38. Diagnostic p53 immunostaining of endobiliary brush cytology: Preoperative cytology compared with the surgical specimen
39. Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears
40. Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice
41. Clinical significance of K-ras oncogene activation in ampullary neoplasms
42. A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed paraffin-embedded tissues
43. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma
44. Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients
45. DPC4 gene mutation in colitis associated neoplasia
46. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma
47. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors
48. Evaluation of candidate tumor suppressor genes on chromosome 18 in colorectal cancers
49. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo
50. DPC4/SMAD4 gene alterations in human cancer, and their functional implications